Literature DB >> 17485907

Current clinical trials of endocrine therapy for breast cancer.

Junichi Kurebayashi1.   

Abstract

Breast cancer is a hormone-dependent cancer like prostate cancer and endometrial cancer. Estrogen plays important roles in the development and progression of breast cancer. Endocrine therapy is the treatment of choice for estrogen receptor- and/or progesterone receptor-positive breast cancer. Endocrine therapy has been used for several purposes, including chemoprevention, preoperative treatment, postoperative adjuvant treatment and treatment for recurrent diseases. A large number of clinical trials have provided evidence showing the clinical benefits of various endocrine therapies for the treatment of breast cancer. The current status and recent advances in endocrine therapy for breast cancer are reviewed based on the results of current clinical trials. Future perspectives of endocrine therapy are also discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17485907     DOI: 10.2325/jbcs.954

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  3 in total

1.  Expression of Protein 4.1 Family in Breast Cancer: Database Mining for 4.1 Family Members in Malignancies.

Authors:  Guan Feng; Kaibo Guo; Qingying Yan; Ye Ye; Minhe Shen; Shanming Ruan; Shengliang Qiu
Journal:  Med Sci Monit       Date:  2019-05-07

2.  Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.

Authors:  Wei-Lan Yeh; Keiko Shioda; Kathryn R Coser; Danielle Rivizzigno; Kristen R McSweeney; Toshi Shioda
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

3.  EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.

Authors:  Alexandra M Pietersen; Hugo M Horlings; Michael Hauptmann; Anita Langerød; Abderrahim Ajouaou; Paulien Cornelissen-Steijger; Lodewijk F Wessels; Jos Jonkers; Marc J van de Vijver; Maarten van Lohuizen
Journal:  Breast Cancer Res       Date:  2008-12-19       Impact factor: 6.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.